This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Taro Pharmaceutical Industries Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Taro Pharmaceutical Industries.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	14.4%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Taro Pharmaceutical Industries Ltd. Is An Overlooked Opportunity

Dec 12

Taro Pharmaceutical: Sun Pharma Deal Uncertain, No Discernible Value Beyond NAV (Rating Downgrade)

Aug 16

Taro Pharmaceutical: Potential Value In Sun Pharma Offer

Jun 02

Taro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate Hold

Feb 24

Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M

Jan 24

Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $30.52M

Oct 28

Taro Pharmaceutical hits 52-week low; down 28% YTD

Aug 15

Taro Pharmaceutical Non-GAAP EPS of $1.09 beats by $0.24, revenue of $156.7M beats by $6.8M

Jul 27

Taro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling Card

Jul 14

We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative

Aug 03

A Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns

Jan 26

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Taro Pharmaceutical Industries has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NYSE:TARO - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2024	629	54	70	125	N/A
12/31/2023	611	46	88	143	N/A
9/30/2023	593	33	97	125	N/A
6/30/2023	575	21	75	98	N/A
3/31/2023	573	25	14	32	N/A
12/31/2022	570	46	2	16	N/A
9/30/2022	569	65	-198	-188	N/A
6/30/2022	571	91	-271	-261	N/A
3/31/2022	561	58	-171	-159	N/A
12/31/2021	566	1	-161	-149	N/A
9/30/2021	568	8	72	86	N/A
6/30/2021	578	29	10	26	N/A
3/31/2021	549	-387	29	46	N/A
12/31/2020	576	-303	22	44	N/A
9/30/2020	583	-268	76	100	N/A
6/30/2020	601	-257	228	253	N/A
3/31/2020	645	244	243	272	N/A
12/31/2019	650	248	252	281	N/A
9/30/2019	678	274	258	289	N/A
6/30/2019	677	281	291	324	N/A
3/31/2019	670	282	293	324	N/A
12/31/2018	665	310	331	363	N/A
9/30/2018	644	234	313	343	N/A
6/30/2018	655	224	304	333	N/A
3/31/2018	662	211	294	324	N/A
12/31/2017	683	208	N/A	343	N/A
9/30/2017	748	330	N/A	384	N/A
6/30/2017	807	401	N/A	454	N/A
3/31/2017	879	457	N/A	438	N/A
12/31/2016	948	489	N/A	476	N/A
9/30/2016	986	538	N/A	458	N/A
6/30/2016	969	547	N/A	383	N/A
3/31/2016	951	541	N/A	395	N/A
12/31/2015	930	579	N/A	454	N/A
9/30/2015	909	532	N/A	440	N/A
6/30/2015	948	542	N/A	439	N/A
3/31/2015	863	485	N/A	407	N/A
12/31/2014	806	422	N/A	277	N/A
9/30/2014	782	395	N/A	294	N/A
6/30/2014	736	348	N/A	329	N/A
3/31/2014	759	361	N/A	358	N/A
12/31/2013	737	321	N/A	349	N/A
9/30/2013	709	294	N/A	327	N/A
6/30/2013	665	263	N/A	294	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if TARO's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if TARO's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if TARO's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if TARO's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if TARO's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if TARO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/06/24 11:26
End of Day Share Price	2024/06/24 00:00
Earnings	2024/03/31
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Taro Pharmaceutical Industries Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Randall Stanicky	Goldman Sachs
Raghuram Selvaraju	H.C. Wainwright & Co.
Kenneth Cacciatore	TD Cowen

This company has been acquired

Taro Pharmaceutical Industries Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to US$54.00

Consensus EPS estimates fall by 12%

Consensus forecasts updated

Price target decreased to US$75.00

Consensus EPS estimates fall by 25%

Recent updates

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) acquired remaining 21.5% stake in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) from Krensavage Asset Management, LLC and others for approximately

Taro Pharmaceutical Shareholders Approve Merger with Sun Pharma and Taro Pharmaceutical Shares to Be De-Listed from the NYSE

Taro Pharmaceutical Industries Ltd. to Report Fiscal Year 2024 Results on May 20, 2024

Taro Pharmaceutical Industries Ltd. to Report Q3, 2024 Results on Jan 25, 2024

Taro Pharmaceutical Industries to Delist from NYSE

Sun Pharma Raises Offer to Buy Taro Pharmaceutical Industries' US Arm

Taro Pharmaceutical Industries Ltd. Is An Overlooked Opportunity

Taro Pharmaceutical Industries Ltd., Annual General Meeting, Dec 28, 2023

Taro Pharmaceutical Industries Ltd. to Report Q2, 2024 Results on Oct 26, 2023

Sun Pharmaceutical Industries Looking to Fully Acquire Its Israel-Based Unit Taro Pharmaceutical Industries

Taro Pharmaceutical: Sun Pharma Deal Uncertain, No Discernible Value Beyond NAV (Rating Downgrade)

Taro Pharmaceutical Industries Ltd. to Report Q1, 2024 Results on Jul 26, 2023

Taro Pharmaceutical Industries Ltd. Appoints Mr. Oded H. Sarig, Ph. D, to Serve as Director

Taro Pharmaceutical Industries Ltd. Announces Resignation of Dov Pekelman from the Board of Directors

Taro Pharmaceutical: Potential Value In Sun Pharma Offer

Taro Pharmaceutical Industries to be Delisted from NYSE

Full year 2023 earnings: EPS misses analyst expectations

Taro Pharmaceutical Industries Ltd. to Report Fiscal Year 2023 Results on May 23, 2023

Investor sentiment improves as stock rises 22%

Investor sentiment deteriorates as stock falls 16%

Taro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate Hold

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M

Taro Pharmaceutical Industries Ltd. to Report Q3, 2023 Results on Jan 24, 2023

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $30.52M

Price target decreased to US$54.00

Taro Pharmaceutical hits 52-week low; down 28% YTD

Full year 2022 earnings: EPS misses analyst expectations

Taro Pharmaceutical Non-GAAP EPS of $1.09 beats by $0.24, revenue of $156.7M beats by $6.8M

Taro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling Card

Consensus EPS estimates fall by 12%

Full year 2022 earnings: EPS misses analyst expectations

Less than half of directors are independent

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$75.00

Consensus EPS estimates fall by 25%

Second quarter 2022 earnings released: EPS US$0.62 (vs US$1.18 in 2Q 2021)

VP, CFO & Chief Accounting Officer Daphne Huang has left the company

We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative

First quarter 2022 earnings released: US$0.50 loss per share (vs US$11.37 loss in 1Q 2021)

Full year 2021 earnings released: US$10.12 loss per share (vs US$6.35 profit in FY 2020)

Full year 2021 earnings released: US$10.12 loss per share (vs US$6.35 profit in FY 2020)

New 90-day high: US$79.95

Third quarter 2021 earnings released: EPS US$0.86 (vs US$1.76 in 3Q 2020)

Revenue and earnings miss expectations

A Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns

New 90-day high: US$72.80

New 90-day high: US$72.47

New 90-day high: US$64.76

Revenue and earnings beat expectations

Second quarter 2021 earnings released: EPS US$1.18

New 90-day low: US$54.40